On the other hand PD-L1 upregulation by IFNγ can contribute to immune evasion and approaches to combining CAR T cells with PD-1/PD-L1 blockade have produced promising results even in hard-to-treat cancers (36). The gene discussed is IFNG; the disease is cancer.